Literature DB >> 17102939

The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.

Zo Rakotoniaina1, Pascal Guerard, Frederic Lirussi, Françoise Goirand, Luc Rochette, Monique Dumas, Marc Bardou.   

Abstract

Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, so called statins, improve endothelial function and exert antiproliferative effects on vascular smooth muscle cells of systemic vessels. This study aimed at comparing the protective effects of two statins, pravastatin and atorvastatin, against monocrotaline (MC)-induced pulmonary hypertension in rats. Pravastatin or atorvastatin (PS or AS, 10 mg/kg per day) or vehicle were given orally for 28 days to Wistar male rats injected or not with MC (60 mg/kg intraperitoneally). At 4 weeks, MC-injected rats developed severe pulmonary hypertension, with an increase in right ventricular pressure (RVP) and right ventricle/left ventricle + septum weight ratio associated with a decrease in acetylcholine- or sodium-nitroprusside-induced pulmonary artery dilation observed in vitro. Hypertensive pulmonary arteries exhibited an increase in medial thickness and endothelial cell apoptosis and a decrease of endothelial nitric oxide synthase (eNOS) expression. MC-rat lungs showed a significant decrease of eNOS (P < 0.01) and increase of cleaved caspase-3 (P < 0.05) expression determined by Western blotting. PS (P = 0.02) but not AS (P = 0.30) significantly limited the development of pulmonary hypertension (RVP in mmHg: 30 +/- 3, 36 +/- 4 vs. 45 +/- 4 and 14 +/- 1 for MC + PS, MC + AS, MC, and control groups, respectively). Both statins significantly reduced MC-induced right ventricle hypertrophy [RV/left ventricular (LV) + S, in mg/g: 0.46 +/- 0.04, 0.39 +/- 0.03, 0.62 +/- 0.05 and 0.29 +/- 0.01 for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05),and reduced MC-induced thickening (61 +/- 6 microm, 82 +/- 5 microm, 154 +/- 4 microm, and 59 +/- 2 microm for MC + PS, MC + AS, MC, and control groups, respectively; P = 0.01) of small intrapulmonary artery medial wall, with MC + AS still being different from the control group. PS but not AS partially restored acetylcholine-induced pulmonary artery vasodilation in MC rats (E(max)=65 +/- 5%, 49 +/- 6%, 46 +/- 3%, and 76 +/- 4% for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05 for MC + PS vs. other groups). Both statins prevented apoptosis and restored eNOS expression of pulmonary artery endothelial cells as well as in the whole lung with a more pronounced effect with PS compared with AS. In conclusion, despite its effects on eNOS expression, apoptosis, and medial wall thickening, AS was unable to significantly reduce pulmonary hypertension and to restore endothelium-dependent relaxation, suggesting intermolecular differences between the two HMG-CoA reductase inhibitors in the protection against MC-induced hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17102939     DOI: 10.1007/s00210-006-0112-z

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  52 in total

1.  Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.

Authors:  R Baetta; E Donetti; C Comparato; M Calore; A Rossi; C Teruzzi; R Paoletti; R Fumagalli; M R Soma
Journal:  Pharmacol Res       Date:  1997-08       Impact factor: 7.658

2.  Potential vascular benefits of statins.

Authors:  Scott Kinlay
Journal:  Am J Med       Date:  2005-12       Impact factor: 4.965

Review 3.  Pulmonary arterial hypertension: new insights and new hope.

Authors:  Kevin B Martin; James R Klinger; Sharon I S Rounds
Journal:  Respirology       Date:  2006-01       Impact factor: 6.424

4.  Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

Authors:  Steeve Provencher; Olivier Sitbon; Marc Humbert; Ségolène Cabrol; Xavier Jaïs; Gérald Simonneau
Journal:  Eur Heart J       Date:  2006-01-23       Impact factor: 29.983

5.  The status of lipid management in 1,836 patients with coronary artery disease: a multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society.

Authors:  Hirotaka Nagashima; Hiroshi Kasanuki
Journal:  J Atheroscler Thromb       Date:  2005       Impact factor: 4.928

6.  Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

Authors:  Robyn J Barst; David Langleben; David Badesch; Adaani Frost; E Clinton Lawrence; Shelley Shapiro; Robert Naeije; Nazzareno Galie
Journal:  J Am Coll Cardiol       Date:  2006-04-24       Impact factor: 24.094

7.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.

Authors:  M Takemoto; K Node; H Nakagami; Y Liao; M Grimm; Y Takemoto; M Kitakaze; J K Liao
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 8.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

9.  Hypoxic vasoconstriction of rat main pulmonary artery: role of endogenous nitric oxide, potassium channels, and phosphodiesterase inhibition.

Authors:  M Bardou; F Goirand; S Marchand; C Rouget; P Devillier; J P Dumas; E J Morcillo; L Rochette; M Dumas
Journal:  J Cardiovasc Pharmacol       Date:  2001-08       Impact factor: 3.105

10.  Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.

Authors:  Laimute Taraseviciene-Stewart; Robertas Scerbavicius; Kang-Hyeon Choe; Carlyne Cool; Kathy Wood; Rubin M Tuder; Nana Burns; Michael Kasper; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-05-12       Impact factor: 5.464

View more
  9 in total

Review 1.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

2.  Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke.

Authors:  Thiago Santos Ferreira; Manuella Lanzetti; Marina Valente Barroso; Carlos Romualdo Rueff-Barroso; Cláudia Farias Benjamim; Lycia de Brito-Gitirana; Luís Cristóvão Porto; Samuel Santos Valença
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

3.  Simvastatin as a treatment for pulmonary hypertension trial.

Authors:  Martin R Wilkins; Omar Ali; William Bradlow; John Wharton; Anne Taegtmeyer; Christopher J Rhodes; Hossein A Ghofrani; Luke Howard; Petros Nihoyannopoulos; Raad H Mohiaddin; J Simon R Gibbs
Journal:  Am J Respir Crit Care Med       Date:  2010-05-15       Impact factor: 21.405

4.  Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.

Authors:  Zo Rakotoniaina; Pascal Guerard; Frédéric Lirussi; Luc Rochette; Monique Dumas; Françoise Goirand; Marc Bardou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-10       Impact factor: 3.000

5.  Exhaled nitric oxide measurement to monitor pulmonary hypertension in a pneumonectomy-monocrotaline rat model.

Authors:  Magdalena Strobl; Catharina Schreiber; Adelheid Panzenböck; Max-Paul Winter; Helga Bergmeister; Johannes Jakowitsch; Julia Mascherbauer; Irene M Lang; Paul Wexberg; Diana Bonderman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-07-26       Impact factor: 5.464

6.  Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells.

Authors:  Omar F Ali; Ellena J Growcott; Ghazwan S Butrous; John Wharton
Journal:  Respir Res       Date:  2011-10-14

7.  Role of oxidative stress versus lipids in monocrotaline-induced pulmonary hypertension and right heart failure.

Authors:  Firoozeh Farahmand; Akshi Malik; Anita Sharma; Ashim K Bagchi; Pawan K Singal
Journal:  Physiol Rep       Date:  2021-11

8.  Efficacy and safety of statin therapy in pulmonary hypertension: a systematic review and meta-analysis.

Authors:  Fangying Chen; Mei Yang; Chun Wan; Lin Liu; Lei Chen
Journal:  Ann Transl Med       Date:  2019-12

9.  The Effects and Mechanism of Atorvastatin on Pulmonary Hypertension Due to Left Heart Disease.

Authors:  Qing Wang; Yi-Zhan Guo; Yi-Tao Zhang; Jiao-Jie Xue; Zhi-Chong Chen; Shi-Yao Cheng; Mao-De Ou; Kang-Lin Cheng; Wei-Jie Zeng
Journal:  PLoS One       Date:  2016-07-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.